Additionally , TRO@ was investigated in a Phase I randomized , double-blind , placebo controlled study to assess the safety , tolerability and pharmacokinetics of single intravenous ascending doses of the compound ( @ to @ mg/kg ) in @ healthy male , post-menopausal and hysterectomized female subjects at flow rates from @ to @ mL/min ( EudraCT number : @-@-@ ) .